Search Results

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Illuminating Functional Selectivity and Allosterism at GPCRs. Date & Time Saturday, November 4th / 11:30 AM Abstract Coming Soon About Stéphane Laporte "Dr. Stéphane Laporte is a Professor of Medicine, and the Director of Research of the Division of Endocrinology and Metabolism at McGill University. He is also an Associate Leader of the Experimental Therapeutics and Metabolism Program and the Director of the Molecular Imaging Platform at the Research Institute of the McGill University Health Centre (RI-MUHC). He is a member of the Executive Committee of the Réseau québécois de recherche sur les médicaments. He has received many awards, including a Canada Research Chair, FRSQ scholarships and the CDA/CSEM/Merck Frosst Young Investigator award. His expertise is in molecular pharmacology and his research program focuses on the molecular and cellular mechanisms regulating G protein-coupled receptor (GPCR) responses, a class of receptors involved in many, if not all, physiological responses, with the ultimate goal of improving drug action. He has developed innovative methods for in-cellulo measurement of protein-protein interactions, receptor trafficking and signalling, useful for drug discovery programs. His research program also studies the allosteric, biased signalling regulation of GPCR and has contributed to the validation of small molecules that block myometrial contraction in pre-term birth. He has contributed to the generation of many intellectual property agreements and patents, and published his findings in high-impact journals. The Canadian Institutes for Health Research and March of Dimes currently support his research." Stéphane Laporte on the web Laporte Lab McGill University LinkedIn Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Atypical Structure and Function of Typical Chemokine Receptors Date & Time Saturday, November 4th / 11:00 AM Abstract Coming Soon About Amy Ramsey "One of the principal efforts of our laboratory is to understand the physiological consequences of NMDA receptor deficiency using genetic mouse models. The NMDA receptor is a subtype of glutamate neurotransmitter receptor that regulates the formation and maintenance of synaptic connections between neurons. It plays an important role in the way that neurons wire together and change the strength of synaptic connections with experience. Our laboratory is interested in the role of NMDA receptors not only on neurons, but also on other cells of the brain such as astrocytes, oligodendrocytes, and endothelial cells. NMDA receptors are implicated in a number of brain disorders including schizophrenia, autism, and epilepsy. Our laboratory has a long-standing interest in the way that NMDA receptors contribute to the symptoms of schizophrenia. Recently, we have focused our efforts on GRIN disorder. This is a rare neurodevelopmental disorder caused by de novo mutations in the GRIN genes that encode NMDA receptors. Although symptoms of GRIN disorder appear very early in childhood, it can take years to reach the right diagnosis through genetic tests. Children with GRIN disorder experience developmental delays, intellectual impairment, visual impairments, and difficulties with daily tasks like talking and walking, feeding and toileting. Many children experience seizures that can be life-threatening. Our laboratory is working to help patients by developing genetically-modified mice that have disease-causing variants in their Grin1 gene. These mice can then be used to test dietary regimens, drugs, and adenoviral gene therapies for their ability to improve specific symptoms. The Ramsey lab uses a combination of biochemical and behavioural approaches to understand the many roles of NMDA receptors and to find treatments for debilitating brain disorders." The Ramsey Lab Amy Ramsey on the web University of Toronto Pubmed Google Scholar LinkedIn Twitter Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Welcome Remarks Date & Time Thursday, November 2nd / 1:30 PM Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Dinner 1 Date & Time Thursday, November 2nd / 8:00 PM Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Discover how GPR65 reshapes our understanding of GPCR signaling and its role in cancer, with Dr. Ian Chronis on the Dr. GPCR podcast. << Back to podcast list Strategic Partner(s) Signals, pH, and Discovery : Cracking GPCR Mysteries with Dr. Ian Chronis In this episode, we welcome Dr. Ian Chronis, a recent Ph.D. graduate preparing to begin his postdoctoral work at the University of Michigan. Host Yamina Berchiche sets a welcoming tone as they dive into Ian’s unique academic journey—from early interests in medicine to his pivot toward pharmacology and GPCR research. His story offers valuable insights for anyone navigating the path from student to scientist. Ian discusses how his experiences at the University of Chicago and the University of Michigan shaped his scientific curiosity, particularly around G protein-coupled receptors (GPCRs) . His research centers on the beta-2 adrenergic receptor and GPR65 , a proton-sensing receptor with promising implications in cancer biology. He shares fascinating findings from his work on GPR65 , highlighting its unusual constitutive internalization and its ability to signal from acidic endosomes. This dual functionality—environmental sensing and compartment-specific signaling—offers a new layer of complexity in GPCR behavior. Yamina underscores the therapeutic potential of GPR65, especially in the context of cancer immunotherapy, and how understanding receptor activity in acidic microenvironments could unlock new therapeutic strategies. Throughout the episode, Ian reflects on the value of a supportive lab culture , the need for better experimental tools in GPCR signaling , and the importance of engaging with the broader GPCR research community to drive innovation. The conversation wraps with a playful exchange about possible podcast titles, with Yamina suggesting "Ancient Greek Chemistry and GPCRs"—a nod to Ian’s heritage and the wide-ranging themes covered. This episode is both educational and inspiring, offering a behind-the-scenes look at a rising scientist’s journey in the ever-evolving world of GPCR research. Summary created by AI About Ian Chronis I recently finished my PhD in the lab of Dr. Manoj Puthenveedu at the University of Michigan, where I am now working as a postdoc. My research has looked at the trafficking and signaling of adrenergic and proton-sensing receptors, with specific focus on identifying novel regulatory proteins governing their function. Ian Chronis on the web LinkedIn Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

GPCR scientist Ben Clements shares how positive allosteric modulators could transform opioid therapy by boosting efficacy and reducing side effects. << Back to podcast list Strategic Partner(s) When to Walk, When to Run: Lessons from the GPCR Trenches with Dr. Ben Clements 1. The Power of Inclusion in the GPCR Field This episode kicks off with a celebration of early-career scientists. Host Dr. Yamina Berchiche emphasizes the importance of diverse voices in the GPCR community: “It’s been a very difficult path to get more early-career scientists on the podcast. But it’s important to make your voice heard.” Benjamin Clements , a postdoctoral fellow at the University of Michigan, joins the conversation as a rising voice in GPCR pharmacology. His journey highlights the transition from general drug development to a deep dive into G protein-coupled receptors. 2. From Aspirations to Application: Ben’s Path into Science Ben shares his winding yet deliberate entry into science. Initially driven by a general passion for biology and a childhood dream of being an astronaut, he began with intestinal choline transport research at UNC. The realization that basic science could impact real patients was transformative. “It’s not just raw science — this can help someone at the end of the day.” – Ben Clements His pivot into neuroscience and pharmacology during grad school at the University of Minnesota laid the groundwork for his current work in GPCR pharmacology. 3. GPCRs and the Opioid Crisis: A New Pharmacological Frontier Now at the University of Michigan, Ben focuses on positive allosteric modulators (PAMs) targeting opioid receptors. The goal: maximize analgesia while minimizing side effects . “We’re enhancing the powerful pain-relieving effects of opioids while limiting respiratory depression, constipation, and abuse liability.” He is particularly excited by the novel application of PAMs in chronic and neuropathic pain models , including the neuroma model , which is typically opioid-insensitive. 4. Allosteric Modulation: The New Frontier of GPCR Drug Discovery Ben reflects on the emerging potential of allosteric modulation in GPCRs — a field that has lagged behind ion channels in clinical applications. “Allosteric modulation in GPCRs is so novel and so exciting. There’s so much availability, so much we don’t know yet.” By working with distinct chemical scaffolds like thiazolidines and xanthinediones, Ben is helping define how structurally different PAMs may act on similar receptor sites. 5. Scientific Rigor: The Value of ‘Old School’ Pharmacology Despite the availability of modern tools, Ben stresses the enduring value of classical methods like GTPγS assays , radioligand binding , and basic PK/PD models . “It doesn’t matter how many cool, fun tools you have. If you don’t understand the math that underlies an allosteric modulator, you won’t understand what’s happening.” This mindset keeps his science grounded, reproducible, and rooted in fundamentals. 6. Mentorship, Team Culture, and the Joy of Science Science is serious work, but Ben believes fun and collaboration fuel great outcomes. At Michigan, his lab balances rigor with light-hearted engagement — like daily squirrel trivia on their whiteboard. “Science is fun. We produce great data, but we also joke around. That’s how we work best.” Strong mentorship, open communication, and peer learning — especially from undergraduate trainees — shape his development as both a scientist and future educator. 7. Translating Discovery into Therapy: Bench to Bedside Vision Ben’s work seeks to merge in vitro mechanistic data with in vivo efficacy , guiding medicinal chemists toward creating druggable PAMs . “The goal is to smash all the amazing biology together and make a drug.” Using site-directed mutagenesis and pharmacological synergy assays , his team aims to understand how and where these compounds interact with the receptor, paving the way for structure-based drug design . 8. Structural Biology Roadblocks: The Cryo-EM Challenge One bottleneck in Ben’s work is visualizing binding sites of PAMs via cryo-EM , due to low compound potency and membrane-embedded binding pockets. “Our compounds don’t bind well enough to be seen clearly. That’s a real challenge with allosterics.” Still, by collaborating with structural biology teams and combining cryo-EM with NMR , his lab is narrowing down potential binding regions. 9. Lessons in Confidence, Collaboration, and Aha Moments From asserting himself as an undergrad to mastering unique techniques in grad school, Ben has accumulated key “aha” moments that shaped his confidence: Standing up to big names when safety was compromised. Realizing his technical skills were indispensable to the team. Discovering breakthrough results in neuroma pain models via a spontaneous collaboration. “We found something incredible — a tenfold shift in the methadone dose-response with our PAM.” 10. Advice for Junior Scientists: Read, Rest, Run Ben closes with wisdom for early-career researchers: “Academia is about knowing when to walk and when to run.” – Advice from Kelsey Flepsen He advocates: Reading one paper a day. Taking care of yourself when possible. Pushing hard when deadlines or breakthroughs demand it. “Your brain’s not a machine. Let it rest. That’s when the best ideas come — in the shower or on a walk.” Summary made with AI ________ Key Takeaway Episode 166 with Ben Clements is a deep dive into the pharmacological potential of GPCRs , the power of mentorship, and the mindset required to thrive in science. With clarity, curiosity, and a collaborative spirit, Ben reminds us that impactful science isn’t just about technology — it’s about people, persistence, and timing. “Science is all about knowing when to walk and knowing when to run.” Keyword Cloud GPCR research community , Dr. GPCR ecosystem , GPCR online course , GPCR scientist network , GPCR drug discovery , GPCR training program , G protein-coupled receptors , GPCR podcast , GPCR webinar series , GPCR data platform Summary created by AI About Ben Clements Dr. Ben M Clements is a behavioral pharmacologist who uses in vitro and in vivo models to discover and characterize novel treatments for chronic pain and opioid use disorder. He received his Ph.D. in Pharmaceutics from the University of Minnesota in 2022, studying the pharmacokinetics and pharmacodynamics of NMDA receptor antagonists. At the University of Michigan, Ben focuses on determining the mechanisms of action of a series of positive allosteric modulators of the mu-opioid receptor. This project involves molecular pharmacology in cell models to determine binding sites and mechanisms of allostery, as well as efficacy studies in mouse and rat models of acute and chronic pain. Dr. Clements' work is primarily focused on translational developments of small molecule therapeutics, and intends to apply these ideas to an independent academic laboratory. In addition, he plans to continue studying how neuromodulators, both exogenous and endogenous, can influence cellular activity, physiological behaviors, and human health. Ben Clements on the web University of Michigan X Google Scholar LinkedIn Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Brian Shoichet About Dr. Brian Shoichet BSc in Chemistry from MIT, Ph.D. with Tack Kuntz at UCSF; Postdoc with Brian Matthews in protein stability-activity tradeoffs, crystallography; started my independent lab at Northwestern University Medical School (1996) was recruited back to UCSF in 2003. Dr. Brian Shoichet on the web Google Scholar Shoichet Lab Twitter Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Timo De Groof About Dr. Timo De Groof Dr. Timo De Groof studied Biochemistry and Biotechnology at the University of Ghent where he graduated in 2015. During his master's studies, he specialized in Biomedical Biotechnology and Structural Biology/Biochemistry. During his last year of studies, Timo performed research in the biopharmaceutical company Argen X and gained experience in the identification and characterization of llama-derived antibodies in inflammatory diseases and oncology. From 2015 to 2019, he completed his Ph.D. in the Medicinal Chemistry group at VU University Amsterdam under the supervision of Prof. Dr. Martine Smit . During his Ph.D., Timo, together with Dr. Raimond Heukers , developed a nanobody platform within the research group and used this platform to develop nanobodies targeting viral G protein-coupled receptors with a special focus on the human cytomegalovirus-encoded chemokine receptor US28. During his Ph.D., he used these nanobodies as research tools, to investigate different GPCR conformations, while also focusing on their therapeutic potential in oncology and transplant infectious disease. Starting from September 2019, Timo started working as a postdoctoral researcher at the Vrije Universiteit Brussel in the In Vivo Cellular and Molecular Imaging (ICMI) group that is focused on translational/clinical applications of nanobodies. He currently is focusing on the development of nanobody-based immuno tracers as part of the IMI/EFPIA project entitled "Immune Image". Moreover, he is closely involved in multiple projects where he focuses on the generation of nanobodies against "difficult-to-target" proteins. In the near future, Timo hopes to combine his previous GPCR experience with his current focus to set up his own research line focusing on translational applications of GPCR-targeting nanobodies. Dr. Timo De Groof on the web LinkedIn Researchgate Twitter Medical Imaging Group Google Scholar Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Pharmacology moves fast. Adaptive thinking—not just tools—keeps you in the game. Join Terry’s Corner for real-world insights from Terry Kenakin. Home → Flash News → ama session sept 18 post 3 “Technologies come and go. If that’s all you know, you’ll be out of the game fast.” Published on October 30, 2025 Category Terry's Corner “Technologies come and go. If that’s all you know, you’ll be out of the game fast.” In our AMA, Terry Kenakin shared timeless career advice for young pharmacologists navigating a fast-changing field: “Try to keep a finger on the pulse of as much as you can… that was one of the main reasons for doing Terry’s Corner. New ideas come up, and if we can encapsulate them and expose them, you can just hit a button, hear about it, and pursue it.” To stay relevant in the next decade, it’s not about chasing the latest assay or tool. It’s about building adaptive thinking—knowing where the field is moving and being ready to pivot with it. That’s what Terry’s Corner was built for: a space to turn decades of industry experience into short, targeted insights that keep you ahead of the curve. 🟢 Join Terry’s Corner → https://www.ecosystem.drgpcr.com/terry-corner ✳️ Next AMA Session: ⚠️ Today, Oct 30 | 12–1 PM EST #GPCR #DrGPCR #Pharmacology #DrugDiscovery #CareerDevelopment #Biotech #Mentorship #EarlyDiscovery #ScientificLeadership Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) Dr. Juan José Fung About Dr. Juan José Fung Dr. Juan José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused on targeting GPCR heteromers in cancer, headquartered in Seoul, Korea, with an R&D facility in the SF Bay Area. Dr. Fung received his Ph.D. from the Stanford University School of Medicine under the mentorship of Dr. Brian Kobilka , studying the dimerization of GPCRs. Dr. Fung continued his Postdoctoral training in Dr. Kobilka’s lab contributing to the elucidation of high-resolution structures of various GPCRs. Dr. Fung has spent significant time in the industry studying membrane proteins, antibodies, and HTS methods for drug discovery. His current work is mainly focused on screening and assay development to bridge the gap between in vitro and in vivo GPCR pharmacology. Dr. Juan José Fung on the web LinkedIn GPCR Therapeutics Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Stephen Ferguson The History of the Great Lakes GPCR Retreat with Dr. Stephen Ferguson About Dr. Stephen Ferguson Dr. Stephen Ferguson is a Professor in the Department of Cellular and Molecular Medicine at the University of Ottawa. He did B.Sc. in biology at McGill University and received his Ph.D. under the mentorship of Dr. Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994). He did his postdoctoral training with Dr. Marc G. Caron at Duke University (1994-1997), where he and his colleagues investigated the role of G protein-coupled receptor kinases and beta-arrestin in regulating G protein-coupled receptor endocytosis, trafficking, and signaling. He has held four Canada Research Chairs since 2001 and was previously a Heart and Stroke Foundation of Canada MacDonald Scholar (1998-2003) and Heart and Stroke Foundation of Ontario Career Investigator (2003-2016). He was a recipient of Canada's Top 40 under 40 award in 2004 and received Queen Elizabeth II, Diamond Jubilee Medal, in 2012. He has also received both Junior (2001) and Senior (2005) investigator awards from the Pharmacological Society of Canada. Most recently, in 2021, he was elected as a Fellow of the Canadian Academy of Health Science (FCAHS). His research career has focused on the investigation of the regulation of G protein-coupled receptors signaling mechanisms in health and disease. He currently holds multiple research grants from the Canadian Institutes of Health Research (CIHR) for his research investigating the role of metabotropic glutamate receptor signaling in Huntington’s and Alzheimer’s disease. Dr. Stephen Ferguson on the web Carlton University Canada Research Chairs Twitter ResearchGate LinkedIn Dr. GPCR Ecosystem Great Lakes GPCR Retreat on the web 21st Great Lakes GPCR Retreat More about previous GPCR Retreat meetings Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → New insights into FPR2 signaling! GRK5 drives FPR2 endocytosis, but β-arrestin plays a pivotal role in postendocytic trafficking, plasma membrane recycling, and regulating signal transduction. Check out the latest GPCR news in the Ecosystem today! You’ll need to register but don’t worry, it’s Free! ➡️https://www.ecosystem.drgpcr.com/receptor-activation-and-signaling/grk5-regulates-endocytosis-of-fpr2-independent-of-%CE%B2-arrestins #gpcr #drgpcr Published on January 30, 2025 Category GPCR Weekly News New insights into FPR2 signaling! GRK5 drives FPR2 endocytosis, but β-arrestin plays a pivotal role in postendocytic trafficking, plasma membrane recycling, and regulating signal transduction. Check out the latest GPCR news in the Ecosystem today! You’ll need to register but don’t worry, it’s Free! ➡️ https:// www.ecosystem.drgpcr.com/receptor-activation-and-signaling/grk5-regulates-endocytosis-of-fpr2-independent-of-%CE%B2-arrestins #gpcr #drgpcr Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) Scott Struthers R. Scott Struthers, Ph.D., is our co-founder and has served as our President and Chief Executive Officer since December 2008. Prior to Crinetics, he was senior director and head of endocrinology and metabolism at Neurocrine Biosciences, Inc., from 1998 to 2008. At Neurocrine, he initiated and led the effort to discover and develop orally active, nonpeptide GnRH antagonists, including elagolix. Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions for the life sciences and higher education markets. Between 1992 to 1995 he led contract research efforts at Biosym Technologies to develop and apply computational tools for drug discovery. In 2021, Dr. Struthers co-founded and serves as board chair at Radionetics Oncology, a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for oncology indications. In addition, he is a member of the board of directors of the San Diego Entrepreneurs Exchange, a nonprofit organization that provides resources for early-stage start-ups, which he co-founded in [2009.] R. Scott Struthers on the web LinkedIn Google Scholar Crinetics Radionetics Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Eleonora Comeo About this episode Eleonora Comeo is a doctoral candidate in Medicinal Chemistry and Drug Discovery in the joint program of the University of Nottingham in the UK and Monash University in Australia. We sat down to chat about GPCRs, synthesizing labeled ligands, and her unique position that allows her to work with GPCR scientists on 2 continents. We also touched on how COVID-19 affected her Ph.D. work. Eleonora Comeo on the web LinkedIn ResearchGate Pubmed Google Scholar Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Nicholas Holliday About Dr. Nicholas Holliday After an undergraduate degree at the University of Cambridge, Nick carried out his Ph.D. at King’s College London, supported by an AJ Clark Ph.D. studentship from the British Pharmacological Society. It was these studies and subsequent postdoctoral work that led to Nick's interest in peptide messengers regulating appetite, metabolism, and the immune system, and the molecular mechanisms underlying the signaling and regulation of their GPCRs. Nick joined the University of Nottingham in 2006, where he is now Associate Professor, establishing a lab focused on G protein-coupled receptor kinetics, signaling, and trafficking and on using novel imaging techniques, such as fluorescent ligands and complementation methods, to investigate the underlying mechanisms. Since 2019, Nick has combined his university role with the leadership of Excellerate Bioscience as Chief Scientific Officer, a contract research organization specializing in molecular and cellular pharmacology. Excellerate is involved in several pre-clinical drug discovery projects for both GPCR and non-GPCR targets, using its expertise in pharmacology to deliver high-quality target validation, lead optimization, and mechanism of action studies for our clients. Dr. Nicholas Holliday on the web LinkedIn ORCID University of Nottingham Twitter Excellerate Bio Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Dopamine-Mediated Motor Recovery after Ischemic Stroke Date & Time Friday, November 3rd / 8:30 AM Abstract Coming Soon About Mario Tiberi "I did my graduate research on the regulation of axonal transport by tricyclic antidepressants (M.Sc.) and molecular pharmacology of opioid receptors (Ph.D.) in the Department of Pharmacology at the Université de Montréal under the mentorship of Dr. Pierre-André Lavoie and Dr. Jacques Magnan, respectively. I then pursued my postdoctoral training at Duke University in the laboratory of Dr. Marc Caron, where I cloned the dopamine D5 receptor gene and investigated the regulation of dopaminergic and adrenergic receptors. My addiction for dopamine led me to the Ottawa Hospital Research Institute (then the Moses and Rose Loeb Research Institute) to develop my independent research program. The Tiberi Lab pursues the study of the molecular, structural, pharmacological and signaling features of dopamine (DA) receptors. We are also currently developing the translational component of our research to capitalize on the druggability potential of GPCRs. More specifically, we investigate the druggability potential of new signaling partners we identified that drive the formation of different DA receptor complexes. We hope our research will aid in the development of new therapeutic interventions for the alleviation of L-DOPA-induced dyskinesia in Parkinson’s Disease and improvement of post-stroke recovery." Mario Tiberi on the web University of Ottawa Pubmed Google Scholar ResearchGate LinkedIn Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Mexico City Nocturnal Tour, Food and drinks Coming Soon < Previous Session Next Session >

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Distinct sub-cellular signal propagation as a component of functional selectivity Date & Time Saturday, November 4th / 8:15 AM Abstract Coming Soon About Michel Bouvier "Michel Bouvier is a professor of Biochemistry and Molecular Medicine and the CEO of the Institute for Research in Immunology and Cancer ( IRIC ) at the Université de Montréal. Following his Ph.D. in Neurological Sciences at the same university in 1985, he completed a post-doctoral fellow at Duke University in the laboratory of Robert Lefkowitz. In 1989, he returned to Montréal as a professor of biochemistry and a scholar of the Medical Research Council of Canada at the Faculty of Medicine of the Université de Montréal. Since 2001, he holds the Canada Research Chair in Signal Transduction and Molecular Pharmacology. Dr. Bouvier is the author of 300 scientific papers and 15 patents and delivered close to 500 invited conferences. He is a world-renowned expert in the field of cell signaling and GPCRs and made seminal contributions to our understanding of this major class of drug targets. In addition to paradigm shifts including inverse agonism, biased signaling, and pharmacological chaperones, his work on bioluminescence resonance energy transfer (BRET) resulted in the development of screening assays that are now widely used for drug discovery. His work received more than 30,000 citations yielding an h-index of 95. He has supervised the research work of 75 graduate students and 40 post-doctoral fellows. Michel’s scientific contributions were recognized by the attribution of many awards and distinctions including his election as a fellow of the Royal Society of Canada (2014), the Julie Axelrod award from the American Society of Pharmacology and Exerimental Therapeutics (2017), the Wilder Penfield award from the Quebec Government (2017), the innovation award of ADRIQ (2019) and the 2021 Killam prize form the Canada Council for the Arts." Michel Bouvier on the web Wikipedia IRIC Bouvier Lab Google Scholar Pubmed ResearchGate Twitter LinkedIn Universite de Montreal- Department of Biochemistry and Molecular Medicine Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule "Have a nice weekend, and I'll see you tomorrow!": RAMP-interacting GPCR Pathways Date & Time Thursday, November 2nd / 4:30 PM Keynote Talk Abstract Coming Soon About Kathleen Caron "Kathleen M. Caron, Ph.D. is the Frederik L. Eldridge Distinguished Professor and Chair of the Department of Cell Biology & Physiology at The University of North Carolina at Chapel Hill—a large, interdisciplinary basic science department consistently ranked in the Top 5 in the Nation in NIH funding. Dr. Caron received a BS in Biology and BA in Philosophy at Emory University and a PhD at Duke University while training with Dr. Keith Parker to elucidate the role of steroidogenesis in regulating sexual determination and adrenal and gonadal development using genetic mouse models. She pursued postdoctoral training with Nobel Laureate Dr. Oliver Smithies at UNC-CH, where she was the first to discover the essential role of adrenomedullin peptide for embryonic survival. With a special emphasis on G protein coupled receptors and receptor activity modifying proteins in vascular biology, the Caron laboratory has gained valuable insights into the genetic basis and pathophysiology of lymphatic vascular disease, preeclampsia and sex-dependent cardiovascular disease. Dr. Caron has received numerous awards including a Burroughs Wellcome Fund Career Award in the Biomedical Sciences, an Established Investigator Award and an Innovator Award from the American Heart Association, a Jefferson Pilot Award in Biomedical Sciences and a UNC-CH Mentoring Award. She currently serves as Associate Editor of Physiological Reviews; the #1 ranked journal in Physiology (IF 46.5). Dr. Caron is also past Associate Editor at JCI and served as the inaugural Associate Editor at ACS-Pharmacology and Translational Science. Dr. Caron currently holds multiple scientific advisory roles in academia, industry and the National Institutes of Health." Kathleen Caron on the web UNC-Chapel Hill Department of Cell Biology and Physiology UNC Lineberger Comprehensive Cancer Center Twitter Google Scholar ORCID ResearchGate Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule A journey from Duke to McGill along the dopamine circuit Date & Time Friday, November 3rd / 8:55 AM Abstract Coming Soon About Bruno Giros "Bruno Giros' lab is dedicated to investigating how molecular changes at the nerve synapse might impact integrated behavior and what we might learn from these mechanisms to cure mental illness. After a doctoral training at the Pierre and Marie Curie University in Paris and a short internship at Genentech Inc. in South San Francisco, he joined the CNRS as a Research Fellow in 1987 in the INSERM Laboratory directed by Jean-Charles Schwartz in Paris, where he cloned and characterized dopamine D2 and D3 receptor subtypes. From 91 to 94, he was an assistant professor at Duke University in North Carolina, working with Marc Caron on the characterization of several neurotransmitter transporters and kinases and establishing the first knock- out for these genes. In 1999, back in France, Dr. Giros created the INSERM/CNRS laboratory on the "Neurobiology of Psychiatric Disorders", at the University of Paris-Sorbonne. Since 2008, he arrived at McGill University with a Canada Research Chair. At McGill, his laboratory has two main axes of research: 1) Studying interindividual vulnerability to chronic stress and depression and; 2) Understand the role of phenotypically defined subpopulations of striatal neurons in motor and cognitive functions." Brunos Giros on the web The Douglas Research Centre McGill University Pubmed Google Scholar LinkedIn Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Coffee Break 3 Date & Time Friday, November 3rd / 10:25 AM Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule A positive Allosteric Modulator of M1 Acetylcholine Receptors Improves Cognitive Deficits in Male and Female Alzheimer’s Mice Date & Time Friday, November 3rd / 1:55 PM About Khaled Abdelrahman Dr. Khaled Abdelrahman graduated in 2006 with a BSc in Pharmaceutical Sciences from Alexandria University (Egypt) followed by MSc in Pharmacology in the same university that was conferred in 2009. He joined the laboratory of Dr. William Cole at the University of Calgary in 2010 for his Ph.D. where he studied the molecular basis underlying altered cerebrovascular function and blood flow in type 2 diabetes. In 2015, He joined Dr. Stephen Ferguson’s laboratory in the Departments of Cellular & Molecular Medicine and Neuroscience at the University of Ottawa as a Postdoctoral Fellow to explore novel G protein-coupled receptor (GPCR) candidates that can be targeted pharmacologically to slow neurodegeneration. He has been also studying what aspects of GPCR signaling are regulated in a sex-selective manner and how this can influence drug discovery in the area of neurodegenerative diseases. He is also a Registered Pharmacist in Canada and held two of the most prestigious Clinician Postdoctoral Fellowships offered by Alberta Innovates and Canadian Institutes of Health Research. He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics. Khaled Abdelrahman on the web University of British Columbia Twitter PubMed Google Scholar Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Cannabinoid compounds to augment L-DOPA treatment in Parkinson's Disease Date & Time Friday, November 3rd / 9:20 AM Abstract Coming Soon About Ali Salahpour "Dr. Salahpour did his undergrad (1993-1996) and PhD (1996-2002) at University of Montreal in the Department of Biochemistry. His PhD work was under the supervision of Dr. Michel Bouvier working on the topic of GPCR dimerization/oligomerization. In November of 2002, he joined the lab of Dr. Marc Caron at Duke University for his post-doctoral training. In the Caron lab, Dr. Salahpour worked on Dopamine Transporter and its role on regulating dopamine transmission and homeostasis. In April 2009, he joined the Department of Pharmacology and Toxicology at University of Toronto and has continued working on dopamine transmission and homeostasis and the role of several of key modulators of the dopamine system, including the dopamine transporter (DAT), the Vesicular Monoamine Transporter 2 (VMAT2), Tyrosine Hydroxylase (TH) and Trace Amine Associate Receptor 1 (TAAR1)." Ali Salahpour on the web University of Toronto Pubmed Google Scholar Twitter Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Home → Flash News → Autoantibodies that activate GPCRs? Wild—but real. Tom Sakmar & Ilana Kotliar break down the link between GPCR autoantibodies, long COVID, and disease signaling in Ep.167 of the Dr.GPCR Podcast This episode is a must if you're thinking diagnostics. 📲 Tap to listen: Ep 167 with Drs. Tom Sakmar & Ilana Kotliar #GPCRautoantibodies #GPCRdrugdiscovery #DrGPCR #Immunology Published on June 3, 2025 Category Dr. GPCR Podcast Autoantibodies that activate GPCRs? Wild—but real. Tom Sakmar & Ilana Kotliar break down the link between GPCR autoantibodies, long COVID, and disease signaling in Ep.167 of the Dr.GPCR Podcast This episode is a must if you're thinking diagnostics. 📲 Tap to listen: Ep 167 with Drs. Tom Sakmar & Ilana Kotliar #GPCRautoantibodies #GPCRdrugdiscovery #DrGPCR #Immunology Previous Next Recent Articles

Home → Flash News → 🚀 New Workshop: Practical Quantification of Allosteric Modulation Join Dr. Terry Kenakin on May 1st, 2025, for an advanced live workshop on allosteric modulators in GPCR drug discovery. Learn how to: ✔️ Identify, measure, and quantify allosteric properties ✔️ Apply functional allosteric models to determine mechanisms of action ✔️ Confirm allostery through kinetic analysis 📅 Date: May 1st, 2025 ⏳ Registration deadline: April 18th 📍 Live on Google Meet 🔗 Register now: https://www.ecosystem.drgpcr.com/event-details-registration/practical-quantification-of-allosteric-modulation #GPCR #Allostery #DrugDiscovery #Pharmacology Published on March 3, 2025 Category GPCR University 🚀 New Workshop: Practical Quantification of Allosteric Modulation Join Dr. Terry Kenakin on May 1st, 2025 , for an advanced live workshop on allosteric modulators in GPCR drug discovery. Learn how to: ✔️ Identify, measure, and quantify allosteric properties✔️ Apply functional allosteric models to determine mechanisms of action✔️ Confirm allostery through kinetic analysis 📅 Date: May 1st, 2025⏳ Registration deadline: April 18th📍 Live on Google Meet 🔗 Register now: https://www.ecosystem.drgpcr.com/event-details-registration/practical-quantification-of-allosteric-modulation #GPCR #Allostery #DrugDiscovery #Pharmacology Previous Next Recent Articles

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Coffee Break 1 Date & Time Thursday, November 2nd / 2:45 PM Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Home → Flash News → 10 GPCR pharmacology lessons. Zero fluff. Launching July 1, Terry’s Corner gives you the clarity and confidence to make better decisions—starting with: • The role of pharmacology in discovery strategy • Black & Leff’s operational model—finally made practical • Binding curves, orthosteric vs allosteric function, and real vs apparent affinity • Molecular dynamics and how they guide ligand design • Why Terry built this—and how it sharpens your next move 📅 Learn anytime. New course every week. 📬 Subscribe to The Kenakin Brief → https://www.terrykenakin.com #GPCRscience #drugdiscovery #TerrysCorner #GPCRpharmacology #ligandbinding Published on June 30, 2025 Category Terry's Corner 10 GPCR pharmacology lessons. Zero fluff. Launching July 1, Terry’s Corner gives you the clarity and confidence to make better decisions—starting with: 🟢 The role of pharmacology in discovery strategy 🟢 Black & Leff’s operational model—finally made practical 🟢 Binding curves, orthosteric vs allosteric function, and real vs apparent affinity 🟢 Molecular dynamics and how they guide ligand design 🟢 Why Terry built this—and how it sharpens your next move 📅 Learn anytime. New course every week. 📬 Subscribe to The Kenakin Brief → https://www.terrykenakin.com #GPCRscience #drugdiscovery #TerrysCorner #GPCRpharmacology #ligandbindingv Previous Next Recent Articles

Home → Flash News → New biosensor technologies are shedding light on GPCR dynamics directly in cells, offering exciting possibilities for multiplexing and miniaturization! Curious about how these advances could impact drug discovery? Check out the latest review on GPCR biosensors. Check out the latest GPCR news in the Ecosystem today! You’ll need to register but don’t worry, it’s Free! Published on October 24, 2024 Category GPCR Weekly News New biosensor technologies are shedding light on GPCR dynamics directly in cells, offering exciting possibilities for multiplexing and miniaturization! Curious about how these advances could impact drug discovery? Check out the latest review on GPCR biosensors. Check out the latest GPCR news in the Ecosystem today! You’ll need to register but don’t worry, it’s Free! ➡️ https:// www.ecosystem.drgpcr.com/reviews/gpcr-biosensors-to-study-conformational-dynamics-and-signaling-in-drug-discovery #GPCR #DrGPCR #biosensor Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) Dr. Caron Tribute Part 1 About Marc Caron Dr. Caron and his family moved to Durham, NC in 1977, following receipt of his BSc in Chemistry from Laval University and his Ph.D. from the University of Miami. He joined the faculty of Laval University School of Medicine in 1975 and then returned to join Duke’s faculty, where he remained as a James B. Duke Professor until his death. He and his laboratory members studied the mechanisms of action and regulation of hormones and neurotransmitters and how they might underlie brain and behavior disorders such as schizophrenia, Parkinson's disease, attention-deficit hyperactivity disorder, mood disorders, and addiction. Among his many honors, Dr. Caron was an investigator of the Howard Hughes Medical Institute from 1992 to 2004, a member of the American Academy of Arts & Sciences, a fellow of the American Association for the Advancement of Science, and a recipient of the Julius Axelrod Award. An authoritative and prolific scientist, with over 650 scientific publications, he is most beloved as a mentor and his relentless encouragement that shaped the careers of hundreds of scientists worldwide. About our panelists in alphabetical order and the year they first met Dr. Caron Dr. Jeffrey Benovic (1985) Dr. Michel Bouvier (1985) Dr. Kathleen Caron - Co-host- (1970) Dr. Richard Cerione (1985) Dr. Brian Kolbilka (1987) Dr. Frederik Leeb-Lundberg (1984) Dr. Robert Lefkowitz (1973) Dr. Lee Limbird (1973) Dr. David Sibley (1988) Memories our panelists shared with us Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Jacob Lee & Jin Choe About this episode In this special episode of the Dr.GPCR podcast , I sat down with the co-founders of Genemod . Jacob Lee and Jin Choe met in ninth grade in English class and have been friends since. Although both went to the same college, Jacob and Jin choose different career paths. One day as they were catching up, Jacob shared his struggles of managing samples and an incredible amount of data and projects in the lab with Jin. Our of this need Genemod was born. Today, Genemod has built a freezer management tool and a project management tool where scientists can manage their reagents, samples, and projects on one intuitive platform. The team is planning on building even more tools that will make Genemod the go-to platform for all research scientists to make research more efficient. Genemode on the web Website Jacob Lee on LinkedIn Jacob Lee on Dr. GPCR Ecosystem Jin Choe on LinkedIn Jin Choe on Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>